Dissection of the Anti-Inflammatory Effect of the Core and C-Terminal (KPV) α-Melanocyte-Stimulating Hormone Peptides
Open Access
- 1 August 2003
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 306 (2) , 631-637
- https://doi.org/10.1124/jpet.103.051623
Abstract
In this study, we analyzed the anti-inflammatory effects of α-melanocyte stimulating hormone (MSH)11–13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis. Systemic treatment of mice with KPV, α-MSH, the core melanocortin peptide His-Phe-Arg-Trp, and the melanocontin receptor 3/4 agonist Ac-Nle4-c[Asp5,d-Phe7,Lys10]NH2 ACTH4-10 (MTII) but not the selective MC1-R agonist H-Ser-Ser-Ile-Ile-Ser-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (MS05) resulted in a significant reduction in accumulation of polymorphonuclear leukocyte in the peritoneal cavity. The antimigratory effect of KPV was not blocked by the MC3/4-R antagonist Ac-Nle4-c[Asp5,d-2Nal7,Lys10]NH2 ACTH4-10 (SHU9119). In vitro, macrophage activation, determined as release of KC and interleukin (IL)-1β was inhibited by α-MSH and MTII but not by KPV. Furthermore, macrophage activation by MTII led to an increase in cAMP accumulation, which was attenuated by SHU9119, whereas KPV failed to increase cAMP. The anti-inflammatory properties of KPV were also evident in IL-1β-induced peritonitis inflammation and in mice with a nonfunctional MC1-R (recessive yellow e/e mice). In conclusion, these data highlight that the C-terminal MSH peptide KPV exhibits an anti-inflammatory effect that is clearly different from that of the core MSH peptides. KPV is unlikely to mediate its effects through melanocortin receptors but is more likely to act through inhibition of IL-1β functions.This publication has 32 references indexed in Scilit:
- Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritisArthritis & Rheumatism, 2002
- MC1 receptors are constitutively expressed on leucocyte subpopulations with antigen presenting and cytotoxic functionsClinical and Experimental Immunology, 2001
- New aspects on the melanocortins and their receptorsPharmacological Research, 2000
- New highly specific agonistic peptides for human melanocortin MC1 receptor☆Published by Elsevier ,2000
- Inhibition of peripheral NF-κB activation by central action of α-melanocyte-stimulating hormoneJournal of Neuroimmunology, 1999
- Mechanisms of the Antiinflammatory Effects of α‐MSH: Role of Transcription Factor NF‐κB and Adhesion Molecule ExpressionAnnals of the New York Academy of Sciences, 1999
- Cyclic lactam .alpha.-melanotropin analogs of Ac-Nle4-cyclo[Asp5,D-Phe7,Lys10]-.alpha.-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptorsJournal of Medicinal Chemistry, 1995
- Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor functionCell, 1993
- α-MSH peptides inhibit acute inflammation induced in mice by rIL-1β, rIL-6, rTNF-α and endogenous pyrogen but not that caused by LTB4, PAF and rIL-8Cytokine, 1992
- Potent and prolonged-acting cyclic lactam analogs of .alpha.-melanotropin: design based on molecular dynamicsJournal of Medicinal Chemistry, 1989